The estimated Net Worth of Stephen W Webster is at least $267 Tisíc dollars as of 2 August 2022. Mr. Webster owns over 7,826 units of Nextcure Inc stock worth over $15,456 and over the last 10 years he sold NXTC stock worth over $2,419. In addition, he makes $249,065 as Independent Director at Nextcure Inc.
Stephen has made over 12 trades of the Nextcure Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 7,826 units of NXTC stock worth $1,487 on 2 August 2022.
The largest trade he's ever made was exercising 20,000 units of Nextcure Inc stock on 20 May 2016 worth over $69,000. On average, Stephen trades about 2,231 units every 57 days since 2015. As of 2 August 2022 he still owns at least 11,447 units of Nextcure Inc stock.
You can see the complete history of Mr. Webster stock trades at the bottom of the page.
Stephen W. Webster serves as Independent Director of the Company. He served as the Chief Financial Officer of Spark Therapeutics, Inc., a publicly traded biotechnology company, from July 2014 until its acquisition by Roche in December 2019. He was previously Senior Vice President and Chief Financial Officer of Optimer Pharmaceuticals, Inc., a publicly traded biotechnology company, from July 2012 until its acquisition by Cubist Pharmaceuticals, Inc. in October 2013. Prior to joining Optimer, Mr. Webster served as SVP and Chief Financial Officer of Adolor Corporation, a biopharmaceutical company, from 2008 until its acquisition by Cubist Pharmaceuticals, Inc. in 2011. From 2007 until joining Adolor Corporation in 2008, Mr. Webster served as Managing Director, Investment Banking Division, Health Care Group for Broadpoint Capital Inc. (formerly First Albany Capital). Mr. Webster served as co-founder, President and Chief Executive Officer for Neuronyx, Inc., a biopharmaceutical company, from 2000 to 2006. Mr. Webster previously served in positions of increased responsibility, including as Director, Investment Banking Division, Health Care Group for PaineWebber Incorporated. Mr. Webster has served as a director of Nabriva Therapeutics AG (formerly Nabriva Therapeutics plc), a publicly traded biopharmaceutical company, since August 2016 and Viking Therapeutics, Inc., a publicly traded biopharmaceutical company, since May 2014. Mr. Webster received an A.B. in economics from Dartmouth College and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.
As the Independent Director of Nextcure Inc, the total compensation of Stephen Webster at Nextcure Inc is $249,065. There are 7 executives at Nextcure Inc getting paid more, with Steven Cobourn having the highest compensation of $993,341.
Stephen Webster is 59, he's been the Independent Director of Nextcure Inc since 2019. There are 12 older and 8 younger executives at Nextcure Inc. The oldest executive at Nextcure Inc is David Kabakoff, 72, who is the Independent Chairman of the Board.
Stephen's mailing address filed with the SEC is C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Nextcure Inc have traded over $0 worth of Nextcure Inc stock and bought 1,475,000 units worth $25,387,500 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Chau Quang Khuong a Timothy M Shannon. On average, Nextcure Inc executives and independent directors trade stock every 48 days with the average trade being worth of $233,653. The most recent stock trade was executed by Kevin N. Heller on 14 July 2020, trading 27,229 units of NXTC stock currently worth $48,195.
nextcure, inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. its lead product candidate is nc318, which is in phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. the company is also developing nc410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called leukocyte-associated immunoglobulin-like receptor 1. its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the b7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. nextcure, inc. has a license agreement with yale university; and a research and development col
Nextcure Inc executives and other stock owners filed with the SEC include: